Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization
[en] Background. Amphetamine administration induces stimulation-independent dopainine release in the nucleus accumbens (NAcc) through reverse dopamine transport, a critical neurochemical event involved in its psycbostimulant action, and, furthermore decreases stimulation-dependent vesicular dopamine release. These effects may involve possible indirect glutamateigic mechanisms. Methods: We investigated the effiects of nitrous oxide and xenon, which possess antagonistic action at the N-methyl-D-aspartate (NMDA) receptor, on brain slices ex vivo on aniphetamine-induced changes in carrier-mediated and KCI-evoked dopamine release in the NAcc, and in vivo on ampbetamine-induced locomotor sensitization Results: Like the low-affininity NMDA receptor antagonist memantine, but not the prototypical compound MK-801, nitrous oxide and xenon at appropriate concentrations blocked both the increase in carrier-mediated dopamine release and locomotor sensitization produced by amphetamine. Conclusions: In contrast to what has generally been found using prototypical NMDA receptor antagonists, these data regarding the effect qf memantine, nitrous oxide, and xenon support the hypothesis that activation qf certain NMDA receptors (possibly those qf containing the NR1a/NR2D subunit) in the NAcc is involved in the ampbetamine-induced increase in carrier-mediated dopamine release and the development qf behavioral sensitization to amphetamine. Nitrous oxide, xenon, and memantine may be of therapeutic interest for treating drug dependence.
Disciplines :
Neurosciences & behavior
Author, co-author :
David, Hélène N.
Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
Lemaire, Michelle ; Centre Hospitalier Universitaire de Liège - CHU > Administration des patients - Expédition
Abraini, Jacques H.
Language :
English
Title :
Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization
Publication date :
01 July 2006
Journal title :
Biological Psychiatry
ISSN :
0006-3223
Publisher :
Elsevier Science Inc, New York, United States - New York
Abraini J.H., Lemaire M., and David H.N. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann NY Acad Sci 1053 (2005) 289-300
Alho H., Methuen T., Paloheimo M., Seppa K., Strid N., Apter-Kaseva N., et al. Nitrous oxide has no effect in the treatment of alcohol withdrawal syndrome. A double-blind placebo-controlled randomized trial. J Clin Psychopharmacol 23 (2003) 211-214
Badiani A., Camp D.M., and Robinson T.E. Enduring enhancement of amphetamine sensitization by drug-associated environmental stimuli. J Pharmacol Exp Ther 282 (1997) 787-794
Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., and Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl) 157 (2001) 1-10
Brazell M.P., Kasser R.J., Renner K.J., Feng J., Moghaddam B., and Adams R.N. Electrocoating carbon fiber microelectrodes with nafion improves selectivity for electroactive neurotransmitters. J Neurosci Methods 22 (1987) 167-172
Bresink I., Benke T.A., Collett V.J., Seal A.J., Parsons C.G., Henley J.M., and Collingridge G.L. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol 119 (1996) 195-204
Burnette W.B., Bailey M.D., Kukoyi S., Blakely R.D., Trowbridge C.G., and Justice Jr. J.B. Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem 68 (1996) 2932-2938
Crespi F., Martin K.F., and Marsden C.A. Simultaneous in vivo voltammetric measurement of striatal extracellular DOPAC and 5-HIAA levels. Effect of electrical stimulation of DA and 5-HT neuronal pathways. Neurosci Lett 90 (1988) 285-291
David H.N., Léveillé F., Chazalviel L., MacKenzie E.T., Buisson A., Lemaire M., and Abraini J.H. Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab 23 (2003) 1168-1173
David H.N., Sissoui K., and Abraini J.H. Modulation of the locomotor responses induced by D1-like and D2-like dopamine receptor agonists and D-amphetamine by NMDA and non-NMDA glutamate receptor agonists and antagonists in the core of the rat nucleus accumbens. Neuropharmacology 46 (2004) 179-191
Daynes G., and Gillman M.A. Psychotropic analgesic nitrous oxide prevents craving after withdrawal for alcohol, cannabis and tobacco. Int J Neurosci 76 (1994) 13-16
Eger II E.I., Saidman L.J., and Brandstater B. Minimum alveolar anesthetic concentration. A standard of anesthetic potency. Anesthesiology 26 (1965) 756-763
Essman W.D., McGonigle P., and Lucki I. Anatomical differentiation within the nucleus accumbens of the locomotor stimulatory actions of selective dopamine agonists and d-amphetamine. Psychopharmacology (Berl) 112 (1993) 233-241
Everitt B., and Wolf M.E. Psychomotor stimulant addiction. a neural systems perspective. J Neurosci 22 (2002) 3312-3320
Fischer J.F., and Cho A.K. Chemical release of dopamine from striatal homogenates. Evidence for an exchange diffusion model. J Pharmacol Exp Ther 208 (1979) 203-209
Floor E., Leventhal P.S., Wang Y., Meng L., and Chen W. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem 64 (1995) 689-699
Floor E., and Meng L. Amphetamine releases dopamine from synaptic vesicles by dual mechanisms. Neurosci Lett 215 (1996) 53-56
Franks N.P., Dickinson R., de Sousa S.L.M., Hall A.C., and Lieb W.R. How does xenon produce anesthesia?. Nature 396 (1998) 324
Gillman M.A., and Lichtigfeld F.J. Correct use of analgesic nitrous oxide for the alcohol withdrawal state is essential. J Clin Psychopharmacol 24 (2004) 238-239
Goto T., Suwa K., Uezono S., Ichinose F., Uchiyama M., and Morita S. The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 80 (1998) 255-256
Green A.L., and el Hait M.A. Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo. J Pharm Pharmacol 30 (1978) 262-263
Heikkila R.E., Orlansky H., Mytilineou C., and Cohen G. Amphetamine. Evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194 (1975) 47-56
Homi H.M., Yokoo N., Ma D., Warner D.S., Franks N.P., Maze M., and Grocott H.P. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 99 (2003) 876-881
Hyman S.E. Addiction to cocaine and amphetamine. Neuron 16 (1996) 901-904
Ikeda K., Araki K., Takayama C., Inoue Y., Yagi T., Aizawa S., and Mishina M. Reduced spontaneous activity of mice defective in the □ 4 subunit of the NMDA receptor channel. Mol Brain Res 33 (1995) 61-71
Jevtovic-Todorovic V., Todorovic S.M., Mennerick S., Powell S., Dikranian K., Benshoff N., et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nature Med 4 (1998) 460-463
Jones S.R., Gainetdinov R.R., Wightman R.M., and Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18 (1998) 1979-1986
Jones S.R., Joseph J.D., Barak L.S., Caron M.G., and Wightman R.M. Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 73 (1999) 2406-2414
Kim J.H., Perugini M., Austin J.D., and Vezina P. Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited. J Neurosci 21 (2001) RC133
Koob G.F., and Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 242 (1988) 715-723
Krasowski M.D., and Harrison N.L. General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci 55 (1999) 1278-1303
Kuhr W.G., Ewing A.G., Near J.A., and Wightman R.M. Amphetamine attenuates the stimulated release of dopamine in vivo. J Pharmacol Exp Ther 232 (1985) 388-394
Laurie D.J., and Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol 268 (1994) 335-345
Liang N.Y., and Rutledge C.O. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol 31 (1982) 983-992
Liang N.Y., and Rutledge C.O. Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem Pharmacol 31 (1982) 2479-2484
Mack F., and Bonisch H. Dissociation constants and lipophilicity of catecholamines and related compounds. Naunyn Schmiedebergs Arch Pharmacol 310 (1979) 1-9
Magendzo K., and Bustos G. Expression of amphetamine-induced behavioral sensitization after short- and long-term withdrawal periods. participation of mu- and delta-opioid receptors. Neuropsychopharmacology 28 (2003) 468-477
Miller D.W., and Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40 (1996) 57-62
Miller H.H., Shore P.A., and Clarke D.E. In vivo monoamine oxidase inhibition by D-amphetamine. Biochem Pharmacol 29 (1980) 1347-1354
Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., and Nabeshima T. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor α4 subunit. J Neurosci 22 (2002) 2335-2342
Montaron M.F., Deniau J.M., Menetrey A., Glowinski J., and Thierry A.M. Prefrontal cortex inputs of the nucleus accumbens-nigro-thalamic circuit. Neuroscience 71 (1996) 371-382
Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (1994) 529-540
Morari M., Marti M., Sbrenna S., Fuxe K., Bianchi C., and Beani L. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem Int 33 (1998) 383-397
Nankai M., Fage D., and Carter C. Striatal NMDA-aspartate receptor subtypes. The pharmacology of N-methyl-D-aspartate-evoked dopamine, gamma-aminobutyric acid, acetylcholine and spermidine release. Eur J Pharmacol 286 (1995) 61-70
Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. NMDA antagonist neurotoxicity mechanism and prevention. Science 254 (1991) 1515-1518
Palmer G.C., and Widzowski D. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids 19 (2000) 151-155
Parker E.M., and Cubeddu L.X. Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J Pharmacol Exp Ther 245 (1988) 199-210
Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development. An update. Drug News Perspect 11 (1998) 523-569
Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
Patel J., Mooslehner K.A., Chan P.M., Emson P.C., and Stamford J.A. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem 85 (2003) 898-910
Porter R.H., and Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers. Implications for therapeutic potential. J Neurochem 64 (1995) 614-623
Pulvirenti L., and Koob G.F. Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci 23 (2002) 151-153
Raiteri M., Cerrito F., Cervoni A.M., and Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 208 (1979) 195-202
Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists. Channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14 (1993) 325-331
Schmitz Y., Lee C.J., Schmauss C., Gonon F., and Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow. Effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 21 (2001) 5916-5924
Seiden L.S., Sabol K.E., and Ricaurte G.A. Amphetamine. Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33 (1993) 639-677
Self D.W., and Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18 (1995) 463-495
Standaert D.G., Landwehrmeyer G.B., Kerner J.A., Penney Jr. J.B., and Young A.B. Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Mol Brain Res 42 (1996) 89-102
Sulzer D., Maidment N.T., and Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60 (1993) 527-535
Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15 (1995) 4102-4108
Sulzer D., and Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules. A mechanism of action. Neuron 5 (1990) 797-808
Vezina P., and Queen A.L. Induction of locomotor sensitization by amphetamine requires the activation of NMDA receptors in the rat ventral tegmental area. Psychopharmacology 151 (2000) 184-191
West A.R., Floresco S.B., Charara A., Rosenkranz J.A., and Grace A.A. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci 1003 (2003) 53-74
Wieczorek W.J., and Kruk Z.L. Differential action of (+)-amphetamine on electrically evoked dopamine overflow in rat brain slices containing corpus striatum and nucleus accumbens. Br J Pharmacol 111 (1994) 829-836
Wilhelm S., Ma D., Maze M., and Franks N.P. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 96 (2002) 1485-1491
Williams K. Pharmacological properties of recombinant N-methyl-D-aspartate (NMDA) receptors containing the epsilon 4 (NR2D) subunit. Neurosci Lett 184 (1995) 181-184
Wise R.A. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19 (1996) 319-340
Wolf M.E., White F.J., and Hu X.T. MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J Neurosci 14 (1994) 1735-1745
Yamakura T., and Harris R.A. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 93 (2000) 1095-1101
Zaczek R., Culp S., and De Souza E.B. Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther 257 (1991) 830-835
Zaczek R., Culp S., Goldberg H., Mccann D.J., and De Souza E.B. Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J Pharmacol Exp Ther 257 (1991) 820-829
